Colonis – Managing Director

Colonis is an innovative pharmaceutical company focused on developing Value-Added Medicines (VAMs) and patient-centred treatment options. The business operates as a wholly owned subsidiary of the Clinigen Group, a leading global pharmaceutical services platform backed by private equity firm Triton Partners.

By combining research excellence with commercial agility, Colonis identifies opportunities to repurpose existing molecules into niche and highly valuable medicines, enabling patients to access treatments that otherwise might not be available.

As part of a succession planning initiative, Colonis required a new Managing Director to replace the incumbent due to retirement. This was a mission-critical hire during a period of international expansion, and time-sensitive to allow for a seamless handover.

The Brief

The new Managing Director needed to combine deep expertise in the life sciences and pharmaceutical sectors with proven international leadership experience. This was not just a replacement appointment — Colonis required a leader capable of steering global growth, delivering investor objectives, and continuing the business’ reputation for innovation in VAM development.

The mandate followed Compass Carter Osborne’s successful track record of executive search work with the parent company Clinigen Group, demonstrating our ability to deliver senior hires across Triton Partners’ healthcare portfolio.

Why Compass Carter Osborne?

Compass Carter Osborne was chosen for its strong reputation in life sciences executive search, particularly in private equity-backed healthcare platforms. The firm’s credibility with both investors and operators, combined with extensive networks in the global pharmaceutical sector, meant it was uniquely positioned to deliver the search to the timescales required.

Search Process & Methodology

Compass Carter Osborne agreed a four-week to shortlist timetable with Colonis and Clinigen. Leveraging both the firm’s established life sciences networks and a comprehensive research-led approach, the team systematically mapped a target pool of 85 candidates across the UK and international markets.

Each candidate underwent rigorous assessment against leadership, operational, and cultural criteria. The process ensured alignment with both Colonis’ succession needs and Triton Partners’ broader investor strategy for Clinigen.

The outcome was a best-in-class shortlist delivered on schedule, with final candidates evidencing both pharmaceutical expertise and commercial leadership at scale.

Outcome

Alan Knox was appointed Managing Director following a structured handover period. He has since made an immediate positive impact, bringing fresh leadership while ensuring continuity of strategy and operations during the transition.